The primary objective of this study was to determine
prevalence of clinically detectable BCRL in women who
attended a “reducing your risk of lymphoedema” class
between 2000 and 2005. In addition, we intended to
observe how ELV and participant perception of BCRL
compared with clinician assessment, so secondary objectives
included determining the number of women with
ELV ≥10 % and patient-perceived BCRL, and the agreement
between all three methods. Finally, we wanted
to know the patient-perceived benefit of attending the
“reducing your risk of lymphoedema” class.